Zuszanna Bago-Horvath

10PUBLICATIONS
54CO-AUTHORS
Predictive and prognostic markersNeurology and neuromuscular diseasesCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer cell biology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 05, 2025
HER2/CEP17 ratio predicts residual cancer burden after neoadjuvant dual HER2 blockade: real-world data in patients with primary HER2-amplified breast cancer.

Myriam Stolz, Alex Farr, Kristina A Tendl-Schulz

|Mar 02, 2025
Prognostic relevance of the neurological symptom burden in brain metastases from breast cancer.

Ariane Steindl, Clara Zach, Luzia Berchtold

|Jan 17, 2025
Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial.

Gabriel Rinnerthaler, Daniel Egle, Rupert Bartsch

|Dec 04, 2021
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.

Qing Zhou, Simon P Gampenrieder, Sophie Frantal

|Aug 12, 2021
The OncoMasTR Test Predicts Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Early-Stage Breast Cancer: A Validation Study in ABCSG Trial 8.

Martin Filipits, Margaretha Rudas, Verena Kainz

|Jan 14, 2021
Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs.

Anna S Berghoff, Yunxiang Liao, Matthia A Karreman

Pageof 2

Frequent Collaborators

4 joint publications

Marija Balic

3 joint publications

Michael Gnant

3 joint publications

Daniel Egle

3 joint publications

Martin Filipits